Phio Pharmaceuticals(PHIO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-May 15, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune ce ...